Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

Ivonescimab demonstrated superior progression-free survival compared to Keytruda, positioning it as a potential leader ...

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

Bicara's lead drug, ficerafusp alfa, is currently in an early-stage study in the U.S. to treat a type of head and neck cancer in combination with Merck's Keytruda. BOSTON, Sept. 12, 2024 (GLOBE ...

Keytruda, manufactured b... "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Originally published on healthday.com, part of the BLOX ...